Amarin Corp Plc (AMRN)

[dogn]

High on Lipoprotein-

https://www.jacc.org/jacc-edge/current

You know you are at a cardiology conference when the busiest booth isn’t the one providing free ice cream, but the one offering complimentary Lp(a) screenings. Likely the greatest concentration of lipid-obsessed people in one room, ACC.24 was constantly buzzing with discussion of Lp(a) and its ramifications for patient care. Elevated Lp(a) levels confer greater cardiovascular risk even when LDL levels are optimal and are not affected by current therapeutic options. The REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial) trial aimed to assess the benefit of icosapent ethyl (IPE) across a range of Lp(a) levels. Nearly 7,000 patients on statin therapy with CV disease were randomized to receive IPE or placebo, had a baseline Lp(a) level assessed, and followed for any major adverse CV events. While IPE did not directly lower Lp(a) levels, the study demonstrated that IPE consistently decreased the occurrence of major CV events, irrespective of the actual Lp(a) level. Additional studies will be needed to better understand how to best address this risk factor.